← Back to headlines
ALK-Abello and Novozymes Raise 2026 Revenue Outlooks After Strong Q2
ALK-Abello has raised its 2026 revenue outlook following an 18% organic sales growth in Q2, while Novozymes also increased its FY26 organic sales growth outlook after a 9.8% Y/Y Q2 revenue increase and announced a €1B share buyback plan.
20 Aug, 07:53 — 20 Aug, 08:25
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (27/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left
Center1
Center (1)
investing-com
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 1 region4/34
US2
ℹAll sources from US region
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
Coverage Timeline
First report: seeking-alpha · 20 Aug, 07:53|Full coverage: 2 · 32m|Window: 32m
Left-leaningCenterRight-leaning
